Health Catalyst (NASDAQ:HCAT) Given Overweight Rating at Cantor Fitzgerald

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating restated by Cantor Fitzgerald in a research report issued on Friday, Benzinga reports. They presently have a $16.00 price objective on the stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 85.19% from the stock’s current price.

HCAT has been the subject of a number of other research reports. Evercore ISI dropped their price objective on shares of Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. JPMorgan Chase & Co. raised their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Stephens lowered their price objective on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Finally, Piper Sandler dropped their target price on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.42.

Health Catalyst Stock Performance

Shares of HCAT traded down $0.19 during trading hours on Friday, reaching $8.64. 158,734 shares of the company traded hands, compared to its average volume of 578,724. Health Catalyst has a 1-year low of $5.42 and a 1-year high of $11.41. The stock has a market cap of $510.06 million, a P/E ratio of -4.68 and a beta of 1.31. The stock’s fifty day moving average is $7.25 and its 200 day moving average is $6.92.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. The company had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The company’s quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.21) EPS. On average, equities research analysts predict that Health Catalyst will post -0.35 EPS for the current year.

Insider Transactions at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at $954,572.25. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of the stock in a transaction on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the transaction, the chief operating officer now directly owns 155,215 shares in the company, valued at approximately $954,572.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,361 shares of company stock worth $248,033. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its stake in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after purchasing an additional 5,232 shares during the period. Quarry LP boosted its holdings in Health Catalyst by 59.4% during the second quarter. Quarry LP now owns 7,002 shares of the company’s stock worth $45,000 after buying an additional 2,610 shares during the last quarter. Perfromance Wealth Partners LLC acquired a new position in shares of Health Catalyst during the 2nd quarter worth about $64,000. Mackenzie Financial Corp bought a new stake in shares of Health Catalyst in the 2nd quarter valued at about $70,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Health Catalyst in the 1st quarter valued at about $98,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.